Cambridge Biomedical Exhibiting at Massachusetts CRO/CMO Symposium and Merck Technology Symposium

Merck Technology Symposium

We will be attending the Merck Technology  Symposium on May 6-7th  please drop by our booth (#56).

Merck Technology  Symposium May 6-7th,  Ocean Place Conference Center, Long Branch, NJ


CRO/CMO Symposium

Cambridge Biomedical will be exhibiting at the Massachusetts CRO/CMO Symposium in Burlington on Monday May 5th. We would be pleased to meet with you and discuss your bioanalytical CRO needs at our booth (#11).


Barbara Osband, Cambridge Biomedical’s President & C.E.O.  will be presenting ‘A Successful Massachusetts CRO – My Personal Journey’  and Dr. John Reddington, C.O.O., will be moderating a discussion on  ‘Simplifying the Drug Development Journey From Research to Treatment’.


Now in its third year, the Massachusetts CRO/CMO Symposium shines a spotlight on the strength and success of the CRO and CMO communities in the Commonwealth. The Symposium draws more than 300 attendees to discuss and evaluate the best alternatives that have evolved in shortening time to market. A series of case studies, interactive panel discussions, and networking sessions provide ample time to explore the various techniques and approaches being used by both virtual and established companies.


Location: Burlington Marriott, 1 Burlington Mall Rd, Burlington MA



Exhibit Hall Map


Cambridge Biomedical


Since 1997 Cambridge Biomedical has provided a customer focused approach to support our clients by providing a diverse range of bioanalytical services from pre-clinical to post market. These include; assay development, optimization, validation and diagnostic testing. Conveniently located in Boston to support the pharmaceutical development market with a global reach and with an extensive range of platforms to suit your needs.  We deliver personalized project management and rapid turnaround times to expedite your development pipeline.


Cambridge Biomedical News- PCR Video and BMS R&D Symposium

Cambridge Biomedical is  exhibiting today at the Bristol Myers-Squibb R&D Symposium in Princeton N.J. please stop by and say hello if you are also attending.

Cambridge Biomedical at the BMS R&D Symposium

Cambridge Biomedical at the BMS R&D Symposium


We are also very pleased to release the latest  video in our  “Cambridge Biomedical Technical Series” on PCR (Polymerase Chain Reaction). This video is presented by Dr. Sarah Bond and covers the stringent requirements for sample chain of custody and preparation techniques followed by analysis on our Applied Biosystems ViiA 7 system.

Cambridge Biomedical welcomes comments and also suggestions for other topics in our technical video series.


Human skin grown in lab ‘can replace animal testing’

Skin grown in the laboratory can replace animals in drug and cosmetics testing, UK scientists say.

A team led by King’s College London has grown a layer of human skin from stem cells – the master cells of the body.

Stem cells have been turned into skin before, but the researchers say this is more like real skin as it has a permeable barrier.

It offers a cost-effective alternative to testing drugs and cosmetics on animals, they say.

The outermost layer of human skin, known as the epidermis, provides a protective barrier that stops moisture escaping and microbes entering.



The Surprising Evolution of Sex Determination

A core set of genes on the Y chromosome has been retained through much of animal evolution, not just for male sexual development, but also as regulatory genes in a wide array of tissues, according to twostudies published today (April 23) in Nature. Previous research has shown that the Y chromosome has undergone dramatic gene loss, retaining only 3 percent of its ancestral genes, compared to 98 percent for the X chromosome. Two independent teams—one led by David Page at MIT, the other byHenrik Kaessmann and Diego Cortez at the University of Lausanne in Switzerland—studied a wide variety of animals to demonstrate that the Y chromosome eventually developed a stable set of genes.

The Scientist

Aspirin Can Reduce Colorectal Cancer Risks For Those With Specific Gene

The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene. 

The extraordinary finding comes from a multi-institutional team that analyzed data and other material from two long-term studies involving nearly 128,000 participants. The researchers found that individuals whose colons have high levels of a specific gene product — 15-hydroxyprostaglandin dehydrogenase (15-PGDH) RNA — dramatically reduce their chances of developing colorectal cancer by taking aspirin. In contrast, the analgesic provides no benefit to individuals whose colons show low levels of 15-PGDH. 



New Blood, circa 1914

World War I provided testing grounds for novel blood-transfusion techniques.

In a dramatic and widely publicized feat in 1908, French surgeon Alexis Carrel, working at the Rockefeller Institute for Medical Research in New York City, demonstrated the relatively new technique of direct blood transfusion. To save a baby’s life, he connected the artery of a surgeon’s arm with a vein in the leg of the surgeon’s infant daughter. The method, which he and others had been developing for the past couple of years, circumvented the problem of coagulation that had long challenged blood transfusion efforts. As soon as blood is exposed to air, it begins to coagulate; directly connecting the vessels of donor and recipient avoided contact with air altogether.

“Blood could actually flow from individual to individual and really bring people back from death itself,” says Susan Lederer, a professor of medical history and bioethics at the University of Wisconsin School of Medicine and Public Health.



The Scientist

Chronic prostate inflammation tied to nearly double risk of prostate cancer

A new study led by researchers from the Johns Hopkins Kimmel Cancer Center in Baltimore, MD, finds that compared to men with no such signs, men with chronic inflammation in non-cancerous prostate tissue may have nearly double the risk of developing prostate cancer.

The study also finds that the link between chronic prostate inflammation and prostate cancer may be even stronger in men with high grade cancers – those with a Gleason score between 7 and 10. The Gleason score is assessed by looking at cancer cells under a microscope: a higher grade usually means more abnormal-looking cells and the cancer is growing faster.


Full story at MNT

A Face to Remember

Researchers show that a tuning algorithm can make one’s profile photo more memorable.

Standing out in a crowd—and particularly, the crowded world of social media—may become a little easier as MIT researchers develop a clever way to tweak profile photos to play up a person’s most memorable facial features. Aditya Khosla and others at MIT have found a way to make photographs of faces more memorable or more forgettable, opening new doors in the understanding of memory.

The process was detailed in work presented at the International Conference on Computer Vision in Sydney in December 2013 and earned Khosla a Facebook Graduate Fellowship for further research. According to the researchers, such “feature tuning”—which could be extended from memorability to other qualities, like confidence or trustworthiness—has the potential to change everything from one’s profile photo on Facebook to online dating to political campaigns and advertising strategies.

Screen Shot 2014-04-18 at 12.10.23

Full story at The Scientist


Cambridge Biomedical Convention Schedule

We will be attending the following symposia and conventions  during April, May and June. Please let us know if you are able to attend and we would be delighted to meet with you to discuss how we can assist your drug development program.


Study on Mt. Everest shows how people get type 2 diabetes

At over 8,800 meters high, Mount Everest is the highest mountain on Earth, with oxygen levels on the summit a third of those at sea level. Though the inhospitable environment of the mountain is not ideal for conducting studies, researchers have used the high altitude to study how low oxygen levels in the body – known as hypoxia – are linked to the development of insulin resistance.


Results of the study, conducted by researchers at the University of Southampton and University College London (UCL) in the UK, are published in the journal PLOS One.

Their findings come from a 2007 study, called Caudwell Xtreme Everest. This research group is comprised of intensive care doctors, nurses and scientists who conduct experiments on themselves and other volunteers at high altitudes.

The team says they have gained a better understanding of the molecular process involved when some people get type 2 diabetes. When cells fail to respond to insulin in the body, this is known as insulin resistance.

Because insulin helps the body regulate sugar levels, if this process is faulty, then too much sugar in the body can be toxic, leading to type 2 diabetes.

According to the Centers for Disease Control and Prevention (CDC), type 2 diabetes accounts for 90-95% of diabetes cases in the US. It can be prevented through healthy food choices, physical activity and weight loss, however, once it sets in, insulin or oral medication may be required.


Read more at MNT